-
Posted by
Two Blokes Jun 8 -
Filed in
Stock
-
8 views
Shares of Viking Therapeutics (VKTX 2.88%), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues.
